Scientists developed curcumin nanoparticles and evaluated their cytotoxicity in docetaxel (DTX)-resistant castration-resistant prostate cancer (CRPC) cells for the treatment of DTX-resistant CRPC.
1254621 N8EW4QIJ items 1 apa default asc 1
The addition of chelerythrine significantly inhibited the proliferation of androgen-independent prostate cancer DU145 and PC-3 cells at the concentration of 5 and 10 μM, but not on androgen-dependent prostate cancer LNCaP cells as well as normal prostate epithelial cell line PrEC cells.
[Molecular and Cellular Biochemistry]
1254621 4TPRTHZM items 1 apa default asc 1
Scientists hypothesized that designed peptides with a wide spectrum of selective antimicrobial activity will also have anticancer activity, and tested this hypothesis with newly designed peptides.
1254621 8I2RKNLQ items 1 apa default asc 1
Scientists evaluated the antitumor effect of a next‐generation analog of ralaniten as a monotherapy or in combination with enzalutamide in prostate cancer cells that express AR‐V7 that were resistant to enzalutamide.
1254621 IEV78KG5 items 1 apa default asc 1
Researchers confirmed autophagy induction by withaferin A (WA) treatment by transmission electron microscopy using three prostate cancer cell lines. Fourteen common genes altered by 8‐ and 16‐hour exposure to WA were identified from human autophagy PCR array and these results were consistent with the RNA‐seq data.
1254621 77S4K5UA items 1 apa default asc 1
Immunogenic cell death was determined by assessing the release of damage-associated molecular patterns in the prostate cancer-derived cell lines LNCaP, 22RV1 and PC-3.
1254621 4XP9LYBB items 1 apa default asc 1
The authors examined the potential of natural AKR1C3 inhibitors in various prostate cancer cell lines and a three-dimensional co-culture spheroid model consisting of cancer cells and cancer-associated fibroblasts mimicking enzalutamide resistant prostate cancer.
1254621 NA2BLJMC items 1 apa default asc 1
Kafka, M., Mayr, F., Temml, V., Möller, G., Adamski, J., Höfer, J., Schwaiger, S., Heidegger, I., Matuszczak, B., Schuster, D., Klocker, H., Bektic, J., Stuppner, H., & Eder, I. E. (2020). Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer. Cancers, 12(8), 2092. https://doi.org/10.3390/cancers12082092 Cite
Researchers investigated whether the blockade of ABCC1 affects prostate cancer cell proliferation using both in vitro and in vivo models.
1254621 56SECP8B items 1 apa default asc 1
The expression of UGT2B15, UGT2B17, de novo methyltransferases, DNMT3A and DNMT3B was assessed in prostate cancer cells treated with EGF, an EGFR inhibitor PD16893, and the methyltransferase inhibitor, 5-azacytidine, respectively.
1254621 U7KZJJ4Z items 1 apa default asc 1
Palmitic acid decreased the secretion of exosomes in human prostate cancer cells in vitro in a concentration-dependent manner.
6445218 Y7WEFEAT items 1 apa default asc 1
Researchers discovered a promising selectivity of both alkaloids for human prostate cancer cells, including highly drug-resistant lines, compared to non-malignant cells.
6445218 FK6MPDBU items 1 apa default asc 1